Catheter Ablation of Atrial Fibrillation Advent of Second-Generation Technologies∗ by Buch, Eric & Shivkumar, Kalyanam
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 1 2 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 7 . 0 5 6EDITORIAL COMMENTCatheter Ablation of Atrial Fibrillation
Advent of Second-Generation Technologies*Eric Buch, MD, Kalyanam Shivkumar, MD, PHD“Vision is the art of seeing what
is invisible to others.”
—Jonathan Swift (1)A lthough the exact mechanisms by whichpulmonary vein isolation (PVI) results infreedom from paroxysmal atrial ﬁbrillation
(AF) are still the subject of inquiry and debate, this
procedure is an effective alternative to drug therapy
for rhythm control (2). The technique of catheter-
based PVI has evolved through several stages, from
focal ablation within the pulmonary vein (PV) (3), to
segmental ostial isolation (4), and to antral circumfer-
ential and wide-area isolation (5), with or without
additional lesion sets targeting non-PV foci (6) or
modifying atrial substrate. All of these techniques
initially used point-by-point ablation with radiofre-
quency (RF) ablation catheters.
Single-procedure success rates for catheter abla-
tion of paroxysmal AF are in the 60% to 80% range;
however, the procedure is technically demanding,
highly operator-dependent, and carries a substantial
risk of complications. Moreover, regardless of acute
procedural outcome or clinical success, late recon-
nection of PVs is common (7). Therefore, a variety of
technologies have been developed with the goal of
making the procedure shorter, safer, more predict-
able, and more durable. An evolutionary change has
been the incorporation of contact force sensing into
RF ablation catheters, allowing real-time assessment
of catheter-tissue contact and potentially improving*Editorials published in the Journal of the American College of Cardiology
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paper.efﬁcacy and reducing complications, but still re-
quiring a point-by-point lesion set.
Another approach is to apply RF energy at multiple
sites simultaneously around a circular catheter posi-
tioned outside of each PV ostium (8,9). This has the
theoretical advantage of allowing circumferential en-
ergy delivery instead of requiring the operator to move
the ablation catheter to each site around the vein,
which might result in more rapid PVI. In addition,
energy can be applied selectively to certain electrodes,
allowing ﬁne control over how much ablation occurs
at different sites. However, in practice, maintaining
adequate contact between PV antral tissue and each of
the ablation electrodes simultaneously is not always
possible. Another concern is that the level of PVI might
be closer to the vein ostium than the wide-area point-
by-point lesion set favored by many operators. Some
of the technical issues that hampered early adoption
of these catheters have been mitigated (10), but it re-
mains to be seen whether they will become standard
equipment for AF catheter ablation.
Balloon-based technologies are another method of
delivering energy around the PVs to achieve isolation.
High-intensity focused ultrasound appeared prom-
ising as an energy source, with signiﬁcant lesions
created even in the absence of ﬁrm tissue-balloon
contact. Unfortunately, ablation with this catheter
(ProRhythm, Ronkonkoma, New York) caused collat-
eral damage, including phrenic nerve injury and atrio-
esophageal ﬁstula, and human trials were suspended.
One possible explanation for these complications was
the obligate circumferential energy delivery; the
operator could not choose which part of the balloon
would deliver ablative energy or adjust the intensity of
tissue destruction around the balloon. As a result, the
portion of the left atrium adjacent to the esophagus or
phrenic nerve received the same energy as those areas
where deeper lesions were desired.
The most widely used balloon-based technology for
PVI to date is the cryoballoon catheter, with over
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1362100,000 cases performed worldwide (Arctic Front
Advance, Medtronic, Minneapolis, Minnesota). The
catheter delivers nitrous oxide to an inner balloon,
where it undergoes phase change from liquid to gas
resulting in a temperature near 80C. The balloon
catheter has a central lumen for a spiral mapping
catheter to guide balloon position, reduce perforation
risk, and record PV potentials during ablation. A
steerable sheath (FlexCath, Medtronic) facilitates
positioning of the balloon at each PV antrum. Ablation
with this technology has been proven more efﬁcacious
than antiarrhythmic drug therapy in the multicenter,
randomized STOP AF (North American Arctic Front)
trial (11), with an acceptable safety proﬁle, although
11.2% of patients had transient or persistent phrenic
nerve injury. A large, randomized comparison of
RF catheter ablation and cryoballoon has ﬁnished
recruiting patients, and results are expected soon (12).SEE PAGE 1350Given this rapidly expanding array of technologies
for PV isolation, do we really need another balloon-
based ablation catheter? In this issue of the Journal,
Dukkipati et al. (13) report the results of a large ran-
domized trial comparing point-by-point RF catheter
ablation (without contact force sensing) to visually-
guided ablation using a laser balloon (HeartLight,
CardioFocus, Marlborough, Massachusetts). In theory,
this technology has distinct advantages over both
point-by-point ablation and the cryoballoon catheter.
It offers stable catheter position and contiguous
lesions like other balloon-based technologies, along
with an ability to selectively titrate energy to each
part of the circumferential lesion set like point-by-
point RF ablation. In addition, the laser balloon
diameter can be changed dynamically to suit each PV
antrum, and this is the ﬁrst ablation technology to
allow the operator to directly visualize tissue changes
during ablation. However, theoretical advantages
notwithstanding, the value of any ablation technol-
ogy derives from its clinical results.
Before examining those results, we should em-
phasize that RF ablation catheters have improved
since this study was initiated, especially with the
introduction of contact force sensing (14). However,we should also keep in mind that most of the laser
balloon operators were inexperienced, and there was
a trend toward better results with increasing experi-
ence. An obvious strength of this study, as opposed to
those previously published on the laser balloon, was
the prospective, randomized treatment assignment,
which should minimize bias.
Overall, acute procedural results were similar in the
laser balloon and control groups. Procedures were
longer and required more ﬂuoroscopy with the laser
balloon, but both resulted in complete PVI in > 95% of
patients. Although the adverse event rate seems quite
high in both groups (11.8% in laser balloon, 14.5% in
RF), this was largely driven by cardioversion, a Food
and Drug Administration–mandated primary adverse
event. Adverse events besides cardioversion totaled
5.9% in the laser balloon arm and 6.4% in the control
arm. Themost concerning complications with the laser
balloon were a 3.5% risk of persistent diaphragmatic
paralysis and 1.2% risk of stroke, but these estimates
are necessarily imprecise due to the small number of
patients and events. In clinical follow-up, the
recurrence-free survival curves were superimposable,
with both groups showing nearly 40% AF recurrence
rate, somewhat higher than that seen in contemporary
studies on paroxysmal AF ablation.
These initial randomized results are not yet
compelling enough to predict that the laser will
become a major energy source in catheter ablation of
AF, but the early experience is promising and is
another piece of evidence that the days of point-by-
point ablation for PVI are numbered. One day we
might routinely visualize changes in tissue as we
perform catheter ablation, allowing us to see what
has so far been invisible. The advent of second-
generation technologies for catheter ablation also
provides a moment to focus on the fact that we still
need a better understanding of the mechanisms of
this devastating arrhythmia to improve therapeutics.
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